Current Regulatory Status in Canada
Abaloparatide is not approved by Health Canada. The medication, marketed internationally as Tymlos, remains outside the approved drug formulary for Canadian patients despite its regulatory clearance in other major jurisdictions.
This is distinct from drugs that are approved but restricted, or approved with conditions. Abaloparatide has not completed Health Canada's review process, which means:
- It cannot be prescribed by Canadian physicians through conventional channels
- It cannot be dispensed by Canadian pharmacies
- It is not covered by provincial health insurance plans
- Direct importation for personal use remains subject to Canadian border enforcement
Why Hasn't Abaloparatide Been Approved in Canada?
Health Canada's Therapeutic Products Directorate (TPD) has not publicly released a detailed explanation for the lack of approval. However, several factors may influence regulatory timelines:
Manufacturer Priorities: The pharmaceutical company (Radius Health) may prioritize regulatory submissions in larger markets. Canada represents approximately 3% of North American pharmaceutical spending, which can affect submission sequencing.
Regulatory Backlog: Health Canada has historically managed resource constraints that affect review timelines for new molecular entities, particularly in non-urgent therapeutic areas.
Market Competition: Other bone-building agents like teriparatide (Forteo) are already approved and available in Canada, potentially reducing commercial incentive for expedited submission.
Unlike the US FDA or European EMA, Health Canada does not maintain a publicly searchable database of rejected or pending applications for prescription drugs, making it difficult to determine whether a formal application exists.
International Regulatory Context
Abaloparatide's approval status elsewhere provides useful context:
United States: FDA-approved since 2017. The ACTIVE trial data showing 86% reduction in vertebral fractures over 18 months supported this decision. The drug is available by prescription and covered by many US insurance plans.
European Union: EMA-authorised since 2018 under the centralised procedure. It is available in EU member states and the UK.
Australia & New Zealand: Approved by their respective therapeutic goods authorities.
Canada's divergence from these approvals is uncommon for a drug with strong clinical evidence, but not unprecedented. Regulatory decisions can reflect different risk-benefit assessments, local market dynamics, or administrative priorities.
What Canadians Can Legally Access
Approved Alternatives for Osteoporosis:
Canadians diagnosed with osteoporosis have several Health Canada-approved treatment options:
- Teriparatide (Forteo): A similar bone-building injectable approved in Canada. Clinical trials show slightly lower fracture risk reduction than abaloparatide, but well-established safety data and covered in some provincial plans.
- Bisphosphonates (alendronate, risedronate, zoledronic acid): Approved and widely prescribed. These slow bone loss rather than actively build bone.
- Denosumab (Prolia): RANKL inhibitor approved in Canada; slows bone loss and is more convenient (twice-yearly injections).
- Hormone replacement therapy (HRT): Available for postmenopausal osteoporosis, though with nuanced risk-benefit discussion.
- Calcium and vitamin D supplementation: First-line supportive therapy.
Your physician can discuss which option aligns with your fracture risk profile and medical history.
Special Access Programme (SAP)
Health Canada's Special Access Programme allows patients with serious conditions to access unapproved drugs when no suitable alternative exists in Canada. However, SAP has strict criteria:
- The patient must have a serious condition where conventional treatments have failed or are unsuitable
- A physician must make a documented case
- Health Canada reviews each request individually
- Abaloparatide could theoretically be considered under SAP, but given the availability of teriparatide (a comparable bone-building drug), approval is unlikely
Patients interested in exploring this pathway should discuss it with their rheumatologist or endocrinologist, though it is a lengthy process with no guarantee of approval.
Importation and Legal Risk
Canadians cannot legally purchase abaloparatide from US or European pharmacies and import it for personal use, despite being able to bring other medications across the border under specific conditions. Abaloparatide cannot be imported because:
- It is not approved by Health Canada
- Canada Border Services Agency (CBSA) has authority to seize unapproved drugs
- Personal importation of prescription drugs is only permissible for drugs also approved in Canada
Online vendors claiming to ship abaloparatide to Canada are operating illegally, and purchasing from them carries legal risk to the buyer (potential drug trafficking charges) and medical risk (no quality assurance, no medical supervision).
What Might Change This
Abaloparatide approval in Canada is theoretically possible if:
- Radius Health submits a formal New Drug Submission (NDS) to Health Canada
- Health Canada prioritizes the review (potentially through expedited pathways if new clinical data emerges)
- Provincial health ministries decide to fund it on formularies
Currently, there are no public announcements indicating an imminent application. Patients or physicians interested in advocating for submission could contact Health Canada's TPD or their Member of Parliament to request consideration.
Key Takeaway
Abaloparatide remains unapproved in Canada as of 2024. Canadians with osteoporosis should work with their healthcare team to optimize treatment with approved alternatives, particularly teriparatide if a bone-building approach is preferred. The legal pathways to obtain abaloparatide in Canada are extremely limited, and grey-market importation carries both legal and medical risks.